142 related articles for article (PubMed ID: 26490297)
1. Constitutive NF-κB activation in AML: Causes and treatment strategies.
Bosman MC; Schuringa JJ; Vellenga E
Crit Rev Oncol Hematol; 2016 Feb; 98():35-44. PubMed ID: 26490297
[TBL] [Abstract][Full Text] [Related]
2. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
Zhou J; Ching YQ; Chng WJ
Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-κB signaling pathway.
Wang Y; Tang P; Chen Y; Chen J; Ma R; Sun L
Biochem Biophys Res Commun; 2017 Jun; 488(1):60-66. PubMed ID: 28478034
[TBL] [Abstract][Full Text] [Related]
4. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway.
Birkenkamp KU; Geugien M; Schepers H; Westra J; Lemmink HH; Vellenga E
Leukemia; 2004 Jan; 18(1):103-12. PubMed ID: 14574326
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
[TBL] [Abstract][Full Text] [Related]
7. IL-33-dependent NF-κB activation inhibits apoptosis and drives chemoresistance in acute myeloid leukemia.
Yan M; Chen X; Ye Q; Li H; Zhang L; Wang Y
Cytokine; 2024 Aug; 180():156672. PubMed ID: 38852492
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.
Reikvam H; Olsnes AM; Gjertsen BT; Ersvar E; Bruserud Ø
Crit Rev Oncog; 2009; 15(1-2):1-41. PubMed ID: 20136626
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
[TBL] [Abstract][Full Text] [Related]
10. [NF-κB activity in myeloid leukemia stem cells].
Kagoya Y
Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
[TBL] [Abstract][Full Text] [Related]
11. The TAK1-NF-κB axis as therapeutic target for AML.
Bosman MC; Schepers H; Jaques J; Brouwers-Vos AZ; Quax WJ; Schuringa JJ; Vellenga E
Blood; 2014 Nov; 124(20):3130-40. PubMed ID: 25287709
[TBL] [Abstract][Full Text] [Related]
12. [Role of NF-κB inhibitor in Acute Myeloid Leukemia].
Wang WL; Xu QZ; Mu XH; Wang L; Zhang LY; Xu J; Gao YD; Cheng T; Yuan WP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1622-1626. PubMed ID: 28024466
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
Zhang H; Xu H; Zhang R; Zhao X; Liang M; Wei F
Cancer Chemother Pharmacol; 2020 Aug; 86(2):257-266. PubMed ID: 32696214
[TBL] [Abstract][Full Text] [Related]
14. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
15. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
[TBL] [Abstract][Full Text] [Related]
16. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation.
Yang T; Lan J; Huang Q; Chen X; Sun X; Liu X; Yang P; Jin T; Wang S; Mou X
Cell Biochem Biophys; 2015 Jan; 71(1):291-7. PubMed ID: 25358405
[TBL] [Abstract][Full Text] [Related]
17. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
18. [Research Progress on Chemoresistance Mechanism of Nuclear Factor Kappa B Signalling Patheway in Acute Myeloid Leukemia].
Zhang RR; Zhang H; Chen FX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1785-90. PubMed ID: 26708911
[TBL] [Abstract][Full Text] [Related]
19. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
[TBL] [Abstract][Full Text] [Related]
20. [Expression of NF-kappaB mRNA in acute myeloid leukemia].
Liu M; Wei XD; Lü XD; Fan RH; Yin QS; Zhou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):359-62. PubMed ID: 20416168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
